<DOC>
	<DOCNO>NCT00831974</DOCNO>
	<brief_summary>This 12 week study aim assess safety efficacy 2 dos AB1010 patient suffer indolent systemic mastocytosis handicap .</brief_summary>
	<brief_title>Efficacy AB1010 Patients With Systemic Indolent Mastocytosis</brief_title>
	<detailed_description>Efficacy assess base : Pruritus score Number flush per day Pollakyuria ( daily basis ) Number stools per day QLQ-C30 score Hamilton Rating Scale depression</detailed_description>
	<mesh_term>Mastocytosis</mesh_term>
	<criteria>1 . Patients document Indolent systemic mastocytosis handicap ( ISMwh ) least 2 infiltrated* organ ( skin /or bonemarrow and/or internal organ ) . 2 . Bonemarrow , skin internal biopsydocumented mastocytosis evaluable disease . 3 . The absence activate point mutation phosphotransferase domain cKit D816V cKit mutation least one two infiltrated organ : bone marrow and/or skin and/or tissue . 4 . Handicap define least one follow handicap : number flush per day ≥ 1 , pruritus score ≥ 9 , number stool per day ≥ 4 , Pollakyuria ( per day basis ) ≥ 8 , QLQC30 score ≥ 83 , Hamilton rating scale depression ≥ 12 1 . Performance status &gt; 2 ( ECOG ) . 2 . Inadequate organ function , except abnormality due involvement mast cell</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>mastocytosis</keyword>
	<keyword>indolent</keyword>
	<keyword>handicap</keyword>
	<keyword>wild-type</keyword>
	<keyword>systemic</keyword>
	<keyword>D816V mutate</keyword>
</DOC>